Usually represents liver involvement by infectious mononucleosis
Elevated serum transaminase, alkaline phosphatase, and bilirubin levels
Self limited in majority of cases
•
EBV-associated lymphoproliferative disorders
In immunocompromised individuals due to uncontrolled EBV replication
Occurs in 1.0-2.8% of liver transplants
•
Asymptomatic lifelong infection in > 90% of world adult population
Microscopic
•
EBV hepatitis
Diffuse sinusoidal lymphocytic infiltration in Indian file or string of beads pattern
Mixed inflammatory cell infiltrates in portal tracts, consisting predominantly of lymphocytes
Scattered large and irregular (atypical) lymphocytes in sinusoids and portal tracts
•
Hepatic PTLD
Morphology ranges from hepatitis-like to lymphoma
Ancillary Tests
•
Detection of EBV early RNA (EBER) on tissue sections by in situ hybridization
TERMINOLOGY
Abbreviations
•
Epstein-Barr virus (EBV)
Definitions
•
Infection by EBV
In liver, may cause either hepatitis or posttransplant lymphoproliferative disorder (PTLD)
ETIOLOGY/PATHOGENESIS
Infectious Agents
•
Member of herpesvirus family (human herpesvirus-4)
Double-stranded DNA virus
•
Transmission via intimate contact, frequently with saliva of infected person
Infection begins in oropharyngeal lymphoid tissues, particularly tonsils
Viral envelop glycoprotein binds to CD21 (CR2) on B lymphocytes
CLINICAL ISSUES
Epidemiology
•
New infection typically occurs during adolescence or young adulthood in developed countries
Infectious mononucleosis 35-50% of time
•
Typically occurs in 1st few years of life in developing countries with universal seroconversion by 3-4 years of age
Usually asymptomatic
•
Asymptomatic lifelong infection in > 90% of world adult population
•
Dormant or latent in memory B lymphocytes
Can be reactivated
Commonly found in saliva
Presentation
•
Infectious mononucleosis
Incubation time of 4-6 weeks
Fever, fatigue, malaise, sore throat, arthralgia, jaundice, lymphadenopathy, splenomegaly, and hepatomegaly
Self-limited, usually resolves in 1-2 months
•
EBV hepatitis
Usually represents liver involvement by infectious mononucleosis
Seen in immunocompetent and immunocompromised individuals
Hepatomegaly seen in 10-15% of patients
Jaundice seen in ∼ 5% of patients
Elevated serum transaminase, alkaline phosphatase, and bilirubin levels
•
EBV-associated lymphoproliferative disorders
In immunocompromised individuals due to uncontrolled EBV replication
–
Occurs in 1.0-2.8% of liver transplants
–
Accounts for > 50% of all tumors in children and ∼ 15% of all tumors in adults following liver transplantation
–
> 80% of cases occur in the first 2 years after transplantation
–
Host origin in majority of cases, rarely donor origin
–
Negative EBV status at transplantation and heavy immunosuppression for treatment of rejection are major risk factors